Determinants of adverse event occurrence in children with short stature born small for gestational age treated with growth hormone
In short children born SGA, underlying conditions and associated treatments seem to be the main factors associated with AE occurrence, while GH dose was inversely related to AE occurrence.
Authors
- Jean‐Pierre Salles (ORCID: https://orcid.org/0000-0002-0941-8951)
- Agnès Linglart (ORCID: https://orcid.org/0000-0003-3455-002X)
- Marc Nicolino
- R. Coutant (ORCID: https://orcid.org/0000-0002-6332-4243)
- Nazim Benchikh
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Lyon College (US)
- Novo Nordisk (Denmark) (DK)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Bicêtre Hospital (FR)
- Université d'Angers (FR)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fendo.2025.1656966
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk